The Life Sciences team advised Medipost Co. in its strategic agreement with OmniaBio, Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM). Medipost acquired an equity interest in OmniaBio from CCRM for cash of CAD $30 million and is investing an additional CAD $60 million in Notes into OmniaBio. Once launched, OmniaBio will be the largest contract development and manufacturing organization (CDMO) business in Canada.
Medipost is registered on KOSDAQ and is a Korean pharmaceutical company specializing in the stem cell therapeutics field.
OmniaBio is a CDMO producing gene-modified cell therapies and viral vectors.
The Goodwin team was led by John J. Egan, Steven Green, Maggie Beale-Wirsing, and Swetha Gopalakrishnan, with invaluable assistance from Larissa Pinho (Corporate/Life Sciences); Shane Albright (IP/Licensing), Reid Bagwell and Melissa Schwab Wright (Debt).
For more details, read OmniaBio’s press release and Medipost’s press release.